Estrella Immunopharma, Inc.

NASDAQ: ESLA · Healthcare · Biotechnology

PublicHQ EmeryVille, CA · AlamedaCIK 0001844417Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 18DQ —GM —SS 27

v0.1 · 35/100 weight · pillars only

↑ market scale, Altman-Z · ↓ workforce scale, return on assets

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$13.1M

Employees

Market cap

$42.3M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$13.1M-$13.1M2025

Operating income-$13.1M-$13.1M2025

Total assets$3.2M$3.2M2025

Liabilities$13.5M$13.5M2025

Equity-$10.4M-$10.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Estrella Immunopharma, Inc. earned -$13.1M in FY2025 net income.

Peers · Healthcare

PetMed Express, Inc.43D BioXcel Therapeutics, Inc.27D Cell Source, Inc.——Atlas Energy Corp.54D

Neighbors

Alameda →

Lam Research Corporation$18.4B85A Ross Stores, Inc.$22.8B79B+Block, Inc.$24.2B69B PG&E Corporation$24.9B70B Workday, Inc.$9.6B79B+Veeva Systems Inc.$3.2B86A

Key facts

CEOCheng Liu

SectorHealthcare

IndustryBiotechnology

HeadquartersEmeryVille, CA

ExchangeNASDAQ: ESLA

Employees3

IPO date2021-09-14

Latest filings

8-K2026-06-30 DEF 14A2026-05-27 10-Q2026-05-18 10-K2026-03-18 8-K2026-01-13 8-K2026-01-06 8-K2025-12-04 10-Q2025-11-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.